


**SDHB\_TARGETS\_1\_UP, CERVERA\_SDHB\_TARGETS\_1\_UP**



- NAKAYAMA\_SOFT\_TISSUE\_TUMORS\_PCA2\_DN, NAKAYAMA\_SOFT\_TISSUE\_TUMORS\_PCA2\_DN
- ISSAEVA\_MLL2\_TARGETS, ISSAEVA\_MLL2\_TARGETS
- MCMURRAY\_TP53\_HRAS\_COOPERATION\_RESPONSE\_DN, MCMURRAY\_TP53\_HRAS\_COOPERATION\_RESPONSE\_DN
- CHARAFE\_BREAST\_CANCER\_BASAL\_VS\_MESENCHYMAL\_DN, CHARAFE\_BREAST\_CANCER\_BASAL\_VS\_MESENCHYMAL\_DN
- ANDERSEN\_CHOLANGIOCARCINOMA\_CLASS1, ANDERSEN\_CHOLANGIOCARCINOMA\_CLASS1
- FURUKAWA\_DUSP6\_TARGETS\_PCI35\_UP, FURUKAWA\_DUSP6\_TARGETS\_PCI35\_UP
- MIKKELSEN\_MCV6\_ICP\_WITH\_H3K4ME3\_AND\_H3K27ME3, MIKKELSEN\_MCV6\_ICP\_WITH\_H3K4ME3\_AND\_H3K27ME3
- WILLIAMS\_ESR2\_TARGETS\_DN, WILLIAMS\_ESR2\_TARGETS\_DN
- BLANCO\_MELO\_COVID19\_SARS\_COV\_2\_INFECTION\_A594\_CELLS\_UP, BLANCO\_MELO\_COVID19\_SARS\_COV\_2\_INFECTION\_A594\_CELLS\_UP